Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline.

Medicines Co. will receive $270 million up front, comprising $55 million in

Read the full 396 word article

User Sign In